Chloroquine: Modes of action of an undervalued drug

Immunology Letters

Volumn 153, Issue 1-2, 2013, Pages 50-57

  Thomé, Rodolfo ^a   Lopes, Stefanie Costa Pinto ^a   Costa, Fabio Trindade Maranhão ^a   Verinaud, Liana ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Autoimmunity; Chloroquine; Malaria; Transplantation

Indexed keywords

BAFILOMYCIN A1; CATHEPSIN B; CHLOROQUINE; CYCLOPHOSPHAMIDE; FLUOXETINE; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INTERLEUKIN 2; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAMMALIAN TARGET OF RAPAMYCIN; MEPACRINE; METHOTREXATE; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PIPERAZINE DERIVATIVE; PLACEBO; PRIMAQUINE; PROTEIN KINASE B; PROTEIN P51; PROTEIN P53; SAQUINAVIR; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL; XANTHENE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ALLERGIC ENCEPHALOMYELITIS; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; AUTOPHAGY; CELL DEATH; CHEMOPROPHYLAXIS; CYTOKINE RELEASE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOSOME; EYE TOXICITY; FATIGUE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; LYSOSOME; MALARIA; MALARIA FALCIPARUM; NONHUMAN; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA;

AUTOIMMUNITY; CHLOROQUINE; MALARIA; TRANSPLANTATION;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; CHLOROQUINE; DRUG RESISTANCE, BACTERIAL; EYE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYSOSOMES; MALARIA; PLASMODIUM; TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 84882703929     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.07.004     Document Type: Review

References (164)

1. World Health Organization World Malaria Report 2011 2011, World Health Organization, Geneva.
2. A research agenda for malaria eradication: drugs. PLoS Medicine 2011, 8:e1000402. malERA Consultative Group on Drugs.
3. Plowe C.V. The evolution of drug-resistant malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 2009, 103(Suppl. 1):S11-S14.
4. Summers R.L., Nash M.N., Martin R.E. Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics. Cellular and Molecular Life Sciences 2012, 69:1967-1995.
5. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. American Journal of Medicine 1995, 98:156-168.
6. Bezerra E.L., Vilar M.J., da Trindade Neto P.B., Sato E.L. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2005, 52:3073-3078.
7. Ben-Zvi I., Kivity S., Langevitz P., Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clinical Reviews in Allergy & Immunology 2012, 42:145-153.
8. Homewood C.A., Warhurst D.C., Peters W., Baggaley V.C. Lysosomes, pH and the anti-malarial action of chloroquine. Nature 1972, 235:50-52.
9. Chiang G., Sassaroli M., Louie M., Chen H., Stecher V.J., Sperber K. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clinical Therapeutics 1996, 18:1080-1092.
10. Sperber K., Chiang G., Chen H., Ross W., Chusid E., Gonchar M., et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clinical Therapeutics 1997, 19:913-923.
11. Bernstein H.N. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. American Journal of Medicine 1983, 75:25-34.
12. Bernstein H.N. Chloroquine ocular toxicity. Survey of Ophthalmology 1967, 12:415-447.
13. Slater A.F. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacology & Therapeutics 1993, 57:203-235.
14. Coatney G.R. Pitfalls in a discovery: the chronicle of chloroquine. American Journal of Tropical Medicine and Hygiene 1963, 12:121-128.
15. Loeb R.F., Clark W.M., Coatney G.R., Coggeshall T., Dieuaide F.R., Dochez A.R., et al. Activity of a new antimalarial agent, chloroquine (SN 7618). Journal of the American Medical Association 1946, 130:1069.
16. Harinasuta T., Suntharasamai P., Viravan C. Chloroquine-resistant falciparum malaria in Thailand. Lancet 1965, 2:657-660.
17. Sidhu A.B., Verdier-Pinard D., Fidock D.A. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 2002, 298:210-213.
18. Kublin J.G., Cortese J.F., Njunju E.M., Mukadam R.A., Wirima J.J., Kazembe P.N., et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. Journal of Infectious Diseases 2003, 187:1870-1875.
19. Mita T., Kaneko A., Lum J.K., Bwijo B., Takechi M., Zungu I.L., et al. Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. American Journal of Tropical Medicine and Hygiene 2003, 68:413-415.
20. Mwai L., Ochong E., Abdirahman A., Kiara S.M., Ward S., Kokwaro G., et al. Chloroquine resistance before and after its withdrawal in Kenya. Malaria Journal 2009, 8:106.
21. Laufer M.K., Thesing P.C., Eddington N.D., Masonga R., Dzinjalamala F.K., Takala S.L., et al. Return of chloroquine antimalarial efficacy in Malawi. The New England Journal of Medicine 2006, 355:1959-1966.
22. Ndiaye M., Faye B., Tine R., Ndiaye J.L., Lo A., Abiola A., et al. Assessment of the molecular marker of Plasmodium falciparum chloroquine resistance (Pfcrt) in Senegal after several years of chloroquine withdrawal. American Journal of Tropical Medicine and Hygiene 2012, 87:640-645.
23. Wurtz N., Fall B., Pascual A., Diawara S., Sow K., Baret E., et al. Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal. Malaria Journal 2012, 11:197.
24. Gharbi M., Flegg J.A., Hubert V., Kendjo E., Metcalf J.E., Bertaux L., et al. Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000-2011. Malaria Journal 2013, 12:35.
25. Baird J.K. Resistance to therapies for infection by Plasmodium vivax. Clinical Microbiology Reviews 2009, 22:508-534.
26. Rieckmann K.H., Davis D.R., Hutton D.C. Plasmodium vivax resistance to chloroquine. Lancet 1989, 2:1183-1184.
27. Castillo C.M., Osorio L.E., Palma G.I. Assessment of therapeutic response of Plasmodium vivax and Plasmodium falciparum to chloroquine in a Malaria transmission free area in Colombia. Memorias do Instituto Oswaldo Cruz 2002, 97:559-562.
28. Ruebush T.K., Zegarra J., Cairo J., Andersen E.M., Green M., Pillai D.R., et al. Chloroquine-resistant Plasmodium vivax malaria in Peru. American Journal of Tropical Medicine and Hygiene 2003, 69:548-552.
29. Soto J., Toledo J., Gutierrez P., Luzz M., Llinas N., Cedeno N., et al. Plasmodium vivax clinically resistant to chloroquine in Colombia. American Journal of Tropical Medicine and Hygiene 2001, 65:90-93.
30. Sumawinata I.W., Bernadeta Leksana B., Sutamihardja A., Purnomo Subianto B., et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. American Journal of Tropical Medicine and Hygiene 2003, 68:416-420.
31. Ratcliff A., Siswantoro H., Kenangalem E., Wuwung M., Brockman A., Edstein M.D., et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007, 101:351-359.
32. Tjitra E., Anstey N.M., Sugiarto P., Warikar N., Kenangalem E., Karyana M., et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Medicine 2008, 5:e128.
33. Bray P.G., Hawley S.R., Mungthin M., Ward S.A. Physicochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum. Molecular Pharmacology 1996, 50:1559-1566.
34. Slater A.F., Swiggard W.J., Orton B.R., Flitter W.D., Goldberg D.E., Cerami A., et al. An iron-carboxylate bond links the heme units of malaria pigment. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:325-329.
35. Bray P.G., Janneh O., Raynes K.J., Mungthin M., Ginsburg H., Ward S.A. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. Journal of Cell Biology 1999, 145:363-376.
36. Bray P.G., Mungthin M., Ridley R.G., Ward S.A. Access to hematin: the basis of chloroquine resistance. Molecular Pharmacology 1998, 54:170-179.
37. Pagola S., Stephens P.W., Bohle D.S., Kosar A.D., Madsen S.K. The structure of malaria pigment beta-haematin. Nature 2000, 404:307-310.
38. Sullivan D.J., Gluzman I.Y., Russell D.G., Goldberg D.E. On the molecular mechanism of chloroquine's antimalarial action. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:11865-11870.
39. Sullivan D.J., Matile H., Ridley R.G., Goldberg D.E. A common mechanism for blockade of heme polymerization by antimalarial quinolines. Journal of Biological Chemistry 1998, 273:31103-31107.
40. Fitch C.D., Chevli R., Banyal H.S., Phillips G., Pfaller M.A., Krogstad D.J. Lysis of Plasmodium falciparum by ferriprotoporphyrin IX and a chloroquine-ferriprotoporphyrin IX complex. Antimicrobial Agents and Chemotherapy 1982, 21:819-822.
41. Krogstad D.J., Schlesinger P.H. A perspective on antimalarial action: effects of weak bases on Plasmodium falciparum. Biochemical Pharmacology 1986, 35:547-552.
42. Krogstad D.J., Schlesinger P.H., Gluzman I.Y. Antimalarials increase vesicle pH in Plasmodium falciparum. Journal of Cell Biology 1985, 101:2302-2309.
43. Wunsch S., Sanchez C.P., Gekle M., Grosse-Wortmann L., Wiesner J., Lanzer M. Differential stimulation of the Na+/H+ exchanger determines chloroquine uptake in Plasmodium falciparum. Journal of Cell Biology 1998, 140:335-345.
44. Sanchez C.P., Wunsch S., Lanzer M. Identification of a chloroquine importer in Plasmodium falciparum. Differences in import kinetics are genetically linked with the chloroquine-resistant phenotype. Journal of Biological Chemistry 1997, 272:2652-2658.
45. Fitch C.D. Chloroquine resistance in malaria: a deficiency of chloroquine binding. Proceedings of the National Academy of Sciences of the United States of America 1969, 64:1181-1187.
46. Krogstad D.J., Gluzman I.Y., Kyle D.E., Oduola A.M., Martin S.K., Milhous W.K., et al. Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science 1987, 238:1283-1285.
47. Fidock D.A., Nomura T., Talley A.K., Cooper R.A., Dzekunov S.M., Ferdig M.T., et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Molecular Cell 2000, 6:861-871.
48. Kuhn Y., Sanchez C.P., Ayoub D., Saridaki T., van Dorsselaer A., Lanzer M. Trafficking of the phosphoprotein PfCRT to the digestive vacuolar membrane in Plasmodium falciparum. Traffic 2010, 11:236-249.
49. Lakshmanan V., Bray P.G., Verdier-Pinard D., Johnson D.J., Horrocks P., Muhle R.A., et al. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO Journal 2005, 24:2294-2305.
50. Martin R.E., Marchetti R.V., Cowan A.I., Howitt S.M., Broer S., Kirk K. Chloroquine transport via the malaria parasite's chloroquine resistance transporter. Science 2009, 325:1680-1682.
51. Peel S.A. The ABC transporter genes of Plasmodium falciparum and drug resistance. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 2001, 4:66-74.
52. Duraisingh M.T., Cowman A.F. Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Tropica 2005, 94:181-190.
53. Djimde A., Doumbo O.K., Cortese J.F., Kayentao K., Doumbo S., Diourte Y., et al. A molecular marker for chloroquine-resistant falciparum malaria. New England Journal of Medicine 2001, 344:257-263.
54. Babiker H.A., Pringle S.J., Abdel-Muhsin A., Mackinnon M., Hunt P., Walliker D. High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene pfcrt and the multidrug resistance Gene pfmdr1. Journal of Infectious Diseases 2001, 183:1535-1538.
55. Adagu I.S., Warhurst D.C. Plasmodium falciparum: linkage disequilibrium between loci in chromosomes 7 and 5 and chloroquine selective pressure in Northern Nigeria. Parasitology 2001, 123:219-224.
56. Mu J., Ferdig M.T., Feng X., Joy D.A., Duan J., Furuya T., et al. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Molecular Microbiology 2003, 49:977-989.
57. Ngo T., Duraisingh M., Reed M., Hipgrave D., Biggs B., Cowman A.F. Analysis of pfcrt, pfmdr1, dhfr, and dhps mutations and drug sensitivities in Plasmodium falciparum isolates from patients in Vietnam before and after treatment with artemisinin. American Journal of Tropical Medicine and Hygiene 2003, 68:350-356.
58. Wellems T.E., Plowe C.V. Chloroquine-resistant malaria. Journal of Infectious Diseases 2001, 184:770-776.
59. World Health Organization Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000-2010 2010, World Health Organization, Geneva.
60. Martin S.K., Oduola A.M., Milhous W.K. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 1987, 235:899-901.
61. Egan T.J., Kaschula C.H. Strategies to reverse drug resistance in malaria. Current Opinion in Infectious Diseases 2007, 20:598-604.
62. Guantai E., Chibale K. Chloroquine resistance: proposed mechanisms and countermeasures. Current Drug Delivery 2010, 7:312-323.
63. Martin R.E., Butterworth A.S., Gardiner D.L., Kirk K., McCarthy J.S., Skinner-Adams T.S. Saquinavir inhibits the malaria parasite's chloroquine resistance transporter. Antimicrobial Agents and Chemotherapy 2012, 56:2283-2289.
64. De D., Krogstad F.M., Cogswell F.B., Krogstad D.J. Aminoquinolines that circumvent resistance in Plasmodium falciparum in vitro. American Journal of Tropical Medicine and Hygiene 1996, 55:579-583.
65. Ridley R.G., Hofheinz W., Matile H., Jaquet C., Dorn A., Masciadri R., et al. 4-aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant Plasmodium falciparum. Antimicrobial Agents and Chemotherapy 1996, 40:1846-1854.
66. Biot C., Glorian G., Maciejewski L.A., Synthesis Brocard J.S. antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. Journal of Medicinal Chemistry 1997, 40:3715-3718.
67. Sundelin S.P., Terman A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica 2002, 110:481-489.
68. de Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., Van Hoof F. Commentary. Lysosomotropic agents. Biochemical Pharmacology 1974, 23:2495-2531.
69. Fox R.I. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Seminars in Arthritis and Rheumatism 1993, 23:82-91.
70. Mares V., Schultze B., Maurer W. Stability of DNA in Purkinje cell nuclei of the mouse. An autoradiographic study. Journal of Cell Biology 1974, 63:665-674.
71. McChesney E.W., Banks W.F., Sullivan D.J. Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats. Toxicology and Applied Pharmacology 1965, 7:627-636.
72. Wibo M., Poole B. Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1. Journal of Cell Biology 1974, 63:430-440.
73. Leung K.K., Shilton B.H. Chloroquine binding reveals flavin redox switch function of quinone reductase 2. Journal of Biological Chemistry 2013, 288:11242-11251.
74. Gong X., Kole L., Iskander K., Jaiswal A.K. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Research 2007, 67:5380-5388.
75. Kwiek J.J., Haystead T.A., Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry 2004, 43:4538-4547.
76. Long D.J., Iskander K., Gaikwad A., Arin M., Roop D.R., Knox R., et al. Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. Journal of Biological Chemistry 2002, 277:46131-46139.
77. Ahn K.S., Gong X., Sethi G., Chaturvedi M.M., Jaiswal A.K., Aggarwal B.B. Deficiency of NRH:quinone oxidoreductase 2 differentially regulates TNF signaling in keratinocytes: up-regulation of apoptosis correlates with down-regulation of cell survival kinases. Cancer Research 2007, 67:10004-10011.
78. Savarino A., Boelaert J.R., Cassone A., Majori G., Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases. Lancet Infectious Diseases 2003, 3:722-727.
79. Bergmann M., Schutt F., Holz F.G., Kopitz J. Inhibition of the ATP-driven proton pump in RPE lysosomes by the major lipofuscin fluorophore A2-E may contribute to the pathogenesis of age-related macular degeneration. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2004, 18:562-564.
80. Garulli B., Stillitano M.G., Barnaba V., Castrucci M.R. Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo. Clinical and Vaccine Immunology: CVI 2008, 15:1497-1504.
81. Li Z., Jansen M., Pierre S.R., Figueiredo-Pereira M.E. Neurodegeneration: linking ubiquitin/proteasome pathway impairment with inflammation. The International Journal of Biochemistry & Cell Biology 2003, 35:547-552.
82. Gottlieb R.A., Nordberg J., Skowronski E., Babior B.M. Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:654-658.
83. Yoon Y.H., Cho K.S., Hwang J.J., Lee S.J., Choi J.A., Koh J.Y. Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells. Investigative Ophthalmology & Visual Science 2010, 51:6030-6037.
84. Rubinsztein D.C., Gestwicki J.E., Murphy L.O., Klionsky D.J. Potential therapeutic applications of autophagy. Nature Reviews Drug Discovery 2007, 6:304-312.
85. Orvedahl A., Levine B. Eating the enemy within: autophagy in infectious diseases. Cell Death and Differentiation 2009, 16:57-69.
86. Chiu H.C., Kulp S.K., Soni S., Wang D., Gunn J.S., Schlesinger L.S., et al. Eradication of intracellular Salmonella enterica serovar Typhimurium with a small-molecule, host cell-directed agent. Antimicrobial Agents and Chemotherapy 2009, 53:5236-5244.
87. Amaravadi R.K., Lippincott-Schwartz J., Yin X.M., Weiss W.A., Takebe N., Timmer W., et al. Principles and current strategies for targeting autophagy for cancer treatment. Clinical Cancer Research 2011, 17:654-666.
88. Demachi-Okamura A., Torikai H., Akatsuka Y., Miyoshi H., Yoshimori T., Kuzushima K. Autophagy creates a CTL epitope that mimics tumor-associated antigens. PLoS ONE 2012, 7:e47126.
89. Williams M.A., Bevan M.J. Effector and memory CTL differentiation. Annual Review of Immunology 2007, 25:171-192.
90. Kalia S., Dutz J.P. New concepts in antimalarial use and mode of action in dermatology. Dermatology and Therapy 2007, 20:160-174.
91. Macfarlane D.E., Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. Journal of Immunology 1998, 160:1122-1131.
92. Jeong J.Y., Jue D.M. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. Journal of Immunology 1997, 158:4901-4907.
93. Bondeson J., Sundler R. Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis. General Pharmacology 1998, 30:357-366.
94. van den Borne B.E., Dijkmans B.A., de Rooij H.H., le Cessie S., Verweij C.L. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. Journal of Rheumatology 1997, 24:55-60.
95. Jeong J.Y., Choi J.W., Jeon K.I., Jue D.M. Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunology 2002, 105:83-91.
96. Legssyer R., Josse C., Piette J., Ward R.J., Crichton R.R. Changes in function of iron-loaded alveolar macrophages after in vivo administration of desferrioxamine and/or chloroquine. Journal of Inorganic Biochemistry 2003, 94:36-42.
97. Picot S., Peyron F., Donadille A., Vuillez J.P., Barbe G., Ambroise-Thomas P. Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology 1993, 80:127-133.
98. Weber S.M., Levitz S.M. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. Journal of Immunology 2000, 165:1534-1540.
99. Goldman F.D., Gilman A.L., Hollenback C., Kato R.M., Premack B.A., Rawlings D.J. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000, 95:3460-3466.
100. Sperber K. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. Journal of Rheumatology 1993, 20:803-808.
101. Karres I. Chloroquine inhibits proinflammatory cytokine release into human whole blood. American Journal of Physiology 1998, 274:R1058-R1064.
102. Ertel W., Morrison M.H., Ayala A., Chaudry I.H. Chloroquine attenuates hemorrhagic shock-induced immunosuppression and decreases susceptibility to sepsis. Archives of Surgery 1992, 127:70-75. [discussion 75-76].
103. Loehberg C.R., Strissel P.L., Dittrich R., Strick R., Dittmer J., Dittmer A., et al. Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001. Biochemical Pharmacology 2012, 83:480-488.
104. Sperber K., Kalb T.H., Stecher V.J., Banerjee R., Mayer L. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Research and Human Retroviruses 1993, 9:91-98.
105. Yoshimura A., Kuroda K., Kawasaki K., Yamashina S., Maeda T., Ohnishi S. Infectious cell entry mechanism of influenza virus. Journal of Virology 1982, 43:284-293.
106. Shibata M., Aoki H., Tsurumi T., Sugiura Y., Nishiyama Y., Suzuki S., et al. Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine. Journal of General Virology 1983, 64:1149-1156.
107. Ooi E.E., Chew J.S., Loh J.P., Chua R.C. In vitro inhibition of human influenza A virus replication by chloroquine. Virology Journal 2006, 3:39.
108. Di Trani L., Savarino A., Campitelli L., Norelli S., Puzelli S., D'Ostilio D., et al. Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virology Journal 2007, 4:39.
109. Misinzo G., Delputte P.L., Nauwynck H.J. Inhibition of endosome-lysosome system acidification enhances porcine circovirus 2 infection of porcine epithelial cells. Journal of Virology 2008, 82:1128-1135.
110. Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opinion on Investigational Drugs 2006, 15:1507-1522.
111. Sperber K., Louie M., Kraus T., Proner J., Sapira E., Lin S., et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clinical Therapeutics 1995, 17:622-636.
112. Murray S.M., Down C.M., Boulware D.R., Stauffer W.M., Cavert W.P., Schacker T.W., et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. Journal of Virology 2010, 84:12082-12086.
113. Piconi S., Parisotto S., Rizzardini G., Passerini S., Terzi R., Argenteri B., et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011, 118:3263-3272.
114. Soumelis V., Scott I., Gheyas F., Bouhour D., Cozon G., Cotte L., et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001, 98:906-912.
115. Martinson J.A., Montoya C.J., Usuga X., Ronquillo R., Landay A.L., Desai S.N. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrobial Agents and Chemotherapy 2010, 54:871-881.
116. Jiang M.C., Lin J.K., Chen S.S. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine. Biochemical and Biophysical Research Communications 1996, 226:1-7.
117. Fredericksen B.L., Wei B.L., Yao J., Luo T., Garcia J.V. Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. Journal of Virology 2002, 76:11440-11446.
118. Canadian Rheumatology Association Canadian Consensus Conference on hydroxychloroquine. Journal of Rheumatology 2000, 27:2919-2921.
119. Gladman D.D., Urowitz M.B., Senecal J.L., Fortin P.J., Petty R.E., Esdaile J.M., et al. Aspects of use of antimalarials in systemic lupus erythematosus. Journal of Rheumatology 1998, 25:983-985.
120. Rahman A., Isenberg D.A. Systemic lupus erythematosus. New England Journal of Medicine 2008, 358:929-939.
121. Tan E.M. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Advances in Immunology 1989, 44:93-151.
122. Casciola-Rosen L.A., Anhalt G., Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. Journal of Experimental Medicine 1994, 179:1317-1330.
123. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991, 324:150-154.
124. Fessler B.J. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis and Rheumatism 2005, 52:1473-1480.
125. Alarcon G.S. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINAL). Annals of the Rheumatic Diseases 2007, 66:1168-1172.
126. Ruiz-Irastorza G. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006, 15:577-583.
127. Tam L.S., Gladman D.D., Hallett D.C., Rahman P., Urowitz M.B. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. Journal of Rheumatology 2000, 27:2142-2145.
128. Levy R.A. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001, 10:401-404.
129. Lesiak A., Narbutt J., Kobos J., Kordek R., Sysa-Jedrzejowska A., Norval M., et al. Systematic administration of chloroquine in discoid lupus erythematosus reduces skin lesions via inhibition of angiogenesis. Clinical and Experimental Dermatology 2009, 34:570-575.
130. Kreuter A., Gaifullina R., Tigges C., Kirschke J., Altmeyer P., Gambichler T. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Archives of Dermatology 2009, 145:244-248.
131. Ikeda T., Kanazawa N., Furukawa F. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. Journal of Dermatology 2012, 39:531-535.
132. Kuhn A., Ruland V., Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options. Part I. Journal of the American Academy of Dermatology 2011, 65:e179-e193.
133. Momose Y., Arai S., Eto H., Kishimoto M., Okada M. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus. Journal of Dermatology 2013, 40:94-97.
134. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988, 31:315-324.
135. Louzada-Junior P., Freitas M.V., Oliveira R.D., Deghaide N.H., Conde R.A., Bertolo M.B., et al. A majority of Brazilian patients with rheumatoid arthritis HLA-DRB1 alleles carry both the HLA-DRB1 shared epitope and anti-citrunillated peptide antibodies. Brazilian Journal of Medical and Biological Research 2008, 41:493-499.
136. Perricone C., Ceccarelli F., Valesini G. An overview on the genetic of rheumatoid arthritis: a never-ending story. Autoimmunity Reviews 2011, 10:599-608.
137. Takayanagi H. Inflammatory bone destruction and osteoimmunology. Journal of Periodontal Research 2005, 40:287-293.
138. Takayanagi H., Oda H., Yamamoto S., Kawaguchi H., Tanaka S., Nishikawa T., et al. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochemical and Biophysical Research Communications 1997, 240:279-286.
139. Yamada H., Nakashima Y., Okazaki K., Mawatari T., Fukushi J.I., Kaibara N., et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2008, 67:1299-1304.
140. Hashimoto M., Hirota K., Yoshitomi H., Maeda S., Teradaira S., Akizuki S., et al. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. Journal of Experimental Medicine 2009, 207:1135-1143.
141. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annual Review of Immunology 2009, 27:485-517.
142. Felson D.T., Anderson J.J., Meenan R.F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis and Rheumatism 1990, 33:1449-1461.
143. Scott D.L., Dawes P.T., Tunn E., Fowler P.D., Shadforth M.F., Fisher J., et al. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study. British Journal of Rheumatology 1989, 28:128-133.
144. McCarty D.J., Carrera G.F. Intractable rheumatoid arthritis. Treatment with combined cyclophosphamide, azathioprine, and hydroxychloroquine. JAMA: Journal of the American Medical Association 1982, 248:1718-1723.
145. Bunch T.W., O'Duffy J.D., Tompkins R.B., O'Fallon W.M. Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis and Rheumatism 1984, 27:267-276.
146. Gibson T., Emery P., Armstrong R.D., Crisp A.J., Combined Panayi G.S. D-penicillamine and chloroquine treatment of rheumatoid arthritis - a comparative study. British Journal of Rheumatology 1987, 26:279-284.
147. Thome R., Moraes A.S., Bombeiro A.L., Farias A.D., Francelin C., da Costa T.A., et al. Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis. PLoS ONE 2013, 8:e65913.
148. Schultz K.R., Gilman A.L. The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. Leukemia & Lymphoma 1997, 24:201-210.
149. Schultz K.R., Su W.N., Hsiao C.C., Doho G., Jevon G., Bader S., et al. Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production. Biology of Blood and Marrow Transplantation 2002, 8:648-655.
150. Gilman A.L., Beams F., Tefft M., Mazumder A. The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease. Bone Marrow Transplantation 1996, 17:1069-1075.
151. Gilman A.L., Chan K.W., Mogul A., Morris C., Goldman F.D., Boyer M., et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation 2000, 6:327-334.
152. Schultz K.R., Bader S., Paquet J., Li W. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease. Blood 1995, 86:4344-4352.
153. Hobbs H.E., Sorsby A., Freedman A. Retinopathy following chloroquine therapy. Lancet 1959, 2:478-480.
154. Madalena B.V., Oshima A., Serracarbassa P.D. Amsler grid and visual field on screening for chloroquine retinopathy. Arquivos brasileiros de oftalmologia 2012, 75:170-173.
155. Levy G.D. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis and Rheumatism 1997, 40:1482-1486.
156. Marmor M.F., Kellner U., Lai T.Y., Lyons J.S., Meiler W.F. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011, 118:415-422.
157. Marmor M.F., Carr R.E., Easterbrook M., Farjo A.A., Mieler W.F. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002, 109:1377-1382.
158. Rossi P., Fossaluzza V., Gonano L. Localized scleroderma evolving into systemic sclerosis. Journal of Rheumatology 1985, 12:629-630.
159. Raines M.F., Bhargava S.K., Rosen E.S. The blood-retinal barrier in chloroquine retinopathy. Investigative Ophthalmology & Visual Science 1989, 30:1726-1731.
160. Morand E.F., McCloud P.I., Littlejohn G.O. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Annals of the Rheumatic Diseases 1992, 51:1318-1321.
161. Grierson D.J. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Annals of the Rheumatic Diseases 1997, 56:188-190.
162. Mavrikakis I. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 2003, 110:1321-1326.
163. Chen P.M., Gombart Z.J., Chen J.W. Chloroquine treatment of ARPE-19 cells leads to lysosome dilation and intracellular lipid accumulation: possible implications of lysosomal dysfunction in macular degeneration. Cell & Bioscience 2011, 1:10.
164. Chen J.W., Madamanchi N., Madamanchi N.R., Trier T.T., Keherly M.J. Lamp-1 is upregulated in human glioblastoma cell lines induced to undergo apoptosis. Journal of Biomedical Science 2001, 8:365-374.